Filing Flows › NRX Pharmaceuticals (NRXP) › Q3 2025
NRX Pharmaceuticals (NRXP) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
NRX Pharmaceuticals (NRXP) reported revenue of $242K for the third quarter 2025 (Q3 2025).
NRX Pharmaceuticals, Q3 2025: revenue $242K, net loss $5.9M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $242K | — | — |
| Operating profit | −$4.0M | — | — |
| Net earnings | −$5.9M | — | — |
| Operating cash flow | −$2.9M | — | — |
What changed
Revenue was $242K in Q3 2025. Therapy was the largest line at 63% of revenue.
Operating costs exceeded revenue by $4.0M, an operating margin of -1662.8%. The quarter ended with a net loss of $5.9M.
Operating cash flow was −$2.9M. Non-cash charges added back $26K of depreciation and amortization and $68K of share-based compensation. Working capital and other items added $2.9M.
Questions
What was NRX Pharmaceuticals' revenue in the third quarter 2025?
NRX Pharmaceuticals (NRXP) reported revenue of $242K for the third quarter 2025 (Q3 2025).